{"classes":[{"categories":[{"measurements":[{"comment":"NA = Upper confidence limit cannot be estimated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"2.1","upperLimit":"NA","value":"11.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Time from detection of response to disease progression or death, estimated by Kaplan-Meier with 95% confidence interval using the Brookmeyer-Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.\n\nPembrolizumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacogenomic Study: Correlative studies","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"MEDIAN","populationDescription":"Responding patients (CR or PR).","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Duration of Response","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Months"}